Atiprimod
Alternative Names: SKF 106615Latest Information Update: 31 Mar 2022
At a glance
- Originator AnorMED; University of Texas M. D. Anderson Cancer Center
- Developer Callisto Pharmaceuticals
- Class Anti-inflammatories; Antirheumatics; Small molecules; Spiro compounds
- Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunomodulators; Interleukin 1 modulators; Interleukin 6 modulators; Macrophage modulators; Osteoclast modulators; Proto-oncogene protein c-akt inhibitors; STAT3 transcription factor inhibitors; Tumour necrosis factor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Rheumatoid arthritis
Highest Development Phases
- Discontinued Carcinoid tumour; Inflammation; Multiple myeloma; Osteoporosis; Rheumatoid arthritis; Solid tumours
Most Recent Events
- 28 Jan 2009 Preclinical trials in Rheumatoid arthritis in USA (PO)
- 03 Jun 2008 Efficacy and safety data from a phase II trial in Carcinoid tumour presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
- 16 May 2008 Interim efficacy data from a Phase-II trial in Carcinoid tumour released by Callisto Pharmaceuticals